Tirzepatide Cuts Cardiovascular Risk More Than Semaglutide in Sleep Apnea Patients
A real-world study of 15,000+ patients finds tirzepatide outperforms both semaglutide and liraglutide in preventing major cardiac events.
Summary
A large real-world study compared three popular diabetes and obesity medications — tirzepatide, semaglutide, and liraglutide — in patients who have both type 2 diabetes and obstructive sleep apnea, a combination that significantly raises heart risk. Researchers tracked over 15,000 patients for 18 months and found that tirzepatide reduced the risk of major adverse cardiovascular events by 42% compared to liraglutide and 14% compared to semaglutide. Tirzepatide also reduced the likelihood of developing new sleep apnea compared to liraglutide. Benefits were most pronounced in younger, male, and White patients. While these findings are promising, the study is observational and randomized trials are still needed to confirm superiority.
Detailed Summary
Obstructive sleep apnea (OSA) and type 2 diabetes frequently co-occur and together dramatically elevate the risk of heart attack, stroke, and cardiovascular death. Finding medications that simultaneously address metabolic dysfunction and reduce cardiac risk in this high-risk population is a major clinical priority.
This study used a large global federated healthcare database to compare the cardiovascular outcomes of patients with OSA and type 2 diabetes treated with tirzepatide (a dual GIP/GLP-1 receptor agonist) versus liraglutide or semaglutide (GLP-1 receptor agonists). After propensity-score matching to control for confounders, cohorts included approximately 7,836 and 7,394 matched patient pairs respectively, followed over 18 months.
The headline result: tirzepatide reduced the risk of major adverse cardiovascular events (MACE) by 42% compared to liraglutide (HR 0.58) and by 14% compared to semaglutide (HR 0.86). Additionally, tirzepatide reduced the incidence of new sleep apnea diagnoses compared to liraglutide, though not significantly compared to semaglutide. Subgroup analyses showed the strongest cardiovascular benefits in younger, male patients of White ethnicity.
These findings matter clinically because they suggest tirzepatide's dual hormonal mechanism — targeting both GIP and GLP-1 receptors — may confer meaningful additional cardiovascular protection beyond what semaglutide already provides. Given semaglutide's established cardiovascular benefit (from the SUSTAIN-6 and SELECT trials), tirzepatide showing incremental improvement is a noteworthy signal.
Important caveats apply. This is a retrospective observational analysis, meaning unmeasured confounders could influence results despite propensity matching. The study relied on real-world prescribing data, which may reflect selection bias. The authors themselves call for randomized controlled trials to definitively establish superiority. Subgroup findings by age, sex, and ethnicity require replication before guiding personalized treatment decisions.
Key Findings
- Tirzepatide reduced MACE risk by 42% vs. liraglutide and 14% vs. semaglutide over 18 months.
- Tirzepatide also lowered incidence of new sleep apnea diagnoses compared to liraglutide.
- Benefits were most pronounced in younger, male, White patients — subgroups need further study.
- Over 15,000 propensity-matched patients with OSA and type 2 diabetes were analyzed.
- Authors call for randomized controlled trials to confirm tirzepatide's cardiovascular superiority.
Methodology
Retrospective cohort study using a large global federated healthcare database (TriNetX). Propensity-score matching at 1:1 ratio was used to balance confounders across treatment arms, yielding cohorts of ~7,800 patients each. Outcomes were tracked over an 18-month follow-up period.
Study Limitations
This is an observational retrospective study; despite propensity matching, residual confounding cannot be excluded. Subgroup findings (age, sex, ethnicity) are exploratory and should be interpreted cautiously. The full manuscript was not available — this summary is based on the abstract only.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.